<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532957</url>
  </required_header>
  <id_info>
    <org_study_id>KBP7072-1-003</org_study_id>
    <nct_id>NCT04532957</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects</brief_title>
  <official_title>A Phase I, Double Blind, Placebo Controlled, Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of KBP-7072 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, placebo-controlled, multiple oral dose study to evaluate safety,&#xD;
      tolerability, and pharmacokinetic of KBP-7072 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, randomized, placebo-controlled, parallel-group, multiple oral dose&#xD;
      study. Overall, a total of 24 subjects were studied in 3 groups (Groups 1 to 3); with each&#xD;
      group consisting of 8 subjects (6 subjects receiving KBP-7072 and 2 subjects receiving&#xD;
      placebo). Groups 1 and 2 evaluated 100 and 200 mg QD, respectively. The dose level of 150 mg&#xD;
      QD evaluated in Group 3 was determined based on data obtained from Group 2 of this stud&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 11, 2020</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of KBP-7072 by assessing the number and severity of adverse events, laboratory abnormalities, ECGs, vital signs, and physical examinations.</measure>
    <time_frame>Day 1 - 10</time_frame>
    <description>Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC0-tlast),</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours postdose; on Days 4, 7, 8 and 9 predose and on Day 10 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdose.</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: AUC over a dosing interval (AUC0-τ), from time zero to time of last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours postdose; on Days 4, 7, 8 and 9 predose and on Day 10 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdose.</time_frame>
    <description>AUC over a dosing interval (AUC0-τ) - Plamsa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours postdose; on Days 4, 7, 8 and 9 predose and on Day 10 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdose.</time_frame>
    <description>Maximum observed plasma concentration (Cmax) - Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: time of the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours postdose; on Days 4, 7, 8 and 9 predose and on Day 10 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdose.</time_frame>
    <description>Time of the maximum observed plasma concentration (Tmax) - Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: apparent terminal elimination half-life (t1/2)</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours postdose; on Days 4, 7, 8 and 9 predose and on Day 10 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdose.</time_frame>
    <description>Apparent terminal elimination half-life (t1/2) - Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: observed accumulation ratio based on AUC0-τ (ARAUC0-τ)</measure>
    <time_frame>Day 1 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, and 24 hours postdose; on Days 4, 7, 8 and 9 predose and on Day 10 predose and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours postdose.</time_frame>
    <description>Observed accumulation ratio based on AUC0-τ (ARAUC0-τ) - Plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: amount of drug excreted in urine (Ae)</measure>
    <time_frame>Day 1 at predose (spot collection), 0-6, 6-12, and 12-24 hours postdose, on Days 4, 7, 8 and 9 at predose (spot collection) and on Day 10 at 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours postdose.</time_frame>
    <description>Amount of drug excreted in urine (Ae) - Urine</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses 100mg Healthy subjects receive multiple doses of KBP-7072 (100mg) or Placebo (100mg) QD capsules daily for a total of 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses 200mg Healthy subjects receive multiple doses of KBP-7072 (200mg) or Placebo (200mg) QD capsules daily for a total of 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses dose tbd Healthy subjects receive multiple doses of KBP-7072 (tbd) or Placebo(tbd) QD capsules daily for a total of 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-7072</intervention_name>
    <description>QD oral capsules</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo capsules</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females of nonchildbearing potential or males, of any race, between 18 and 50 years of&#xD;
             age, inclusive, at screening.&#xD;
&#xD;
          2. Body mass index between 18.0 and 30.0 kg/m2, inclusive, at screening.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical and ophthalmologic examinations, 12 lead ECG, vital sign measurements, and&#xD;
             clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg,&#xD;
             suspicion of Gilbert's syndrome based on total and direct bilirubin] is not&#xD;
             acceptable) at screening and check in as assessed by the investigator (or designee).&#xD;
&#xD;
          4. Females of nonchildbearing potential defined as permanently sterile or postmenopausal.&#xD;
             Males will agree to use contraception.&#xD;
&#xD;
          5. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the investigator (or designee).&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the investigator (or designee).&#xD;
&#xD;
          3. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy&#xD;
             and hernia repair will be allowed). Cholecystectomy will not be allowed.&#xD;
&#xD;
          4. Alanine aminotransferase or AST ≥ 1 × ULN. Assessments may be repeated once if outside&#xD;
             the range at screening and/or check-in, at the discretion of the investigator.&#xD;
&#xD;
          5. Fibroscan controlled attenuation parameter (CAP) &gt; 238 dB/m and vibration controlled&#xD;
             transient elastography (VCTE) &gt; 7 kPa.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCabe, MD</last_name>
    <role>Study Director</role>
    <affiliation>KBP Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KBP-7072</keyword>
  <keyword>Multiple ascending dose</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Tetracycline</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

